Gene · 1723
Papers2,016
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,016
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Carbon-ion radiotherapy induces ferroptosis and M1 macrophage polarization to inhibit the development of gastric cancer by downregulating DHODH. | Front Med (Lausanne) | 2025 | 40917841 | PubTator, text mining | PubMed |
| Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. | Nat Commun | 2025 | 40897711 | PubTator, text mining | PubMed |
| Observational suspected adverse drug reaction profiles of fluoro-pharmaceuticals and potential mimicry of per- and polyfluoroalkyl substances (PFAS) in the United Kingdom. | PLoS One | 2025 | 40892740 | PubTator, text mining | PubMed |
| Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications. | Cell Death Discov | 2025 | 40855044 | PubTator, text mining | PubMed |
| Target-aware 3D molecular generation based on guided equivariant diffusion. | Nat Commun | 2025 | 40854901 | PubTator, text mining | PubMed |
| ClpP-based MtPTAC technology enables targeted degradation of inner mitochondrial membrane proteins. | Bioorg Med Chem | 2025 | 40834527 | PubTator, text mining | PubMed |
| Viral Reprogramming of Nucleotide Synthesis and Its Impact on Viral Infection. | J Med Virol | 2025 | 40832900 | PubTator, text mining | PubMed |
Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS). | Trials | 2025 | 40830806 | PubTator, text mining | PubMed |
| Dynamic shifts in trophoblast nucleos(t)ide metabolism, transport, and adenosine signaling during gestation and preterm birth. | Sci Rep | 2025 | 40825832 | PubTator, text mining | PubMed |
| Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. | Immunity | 2025 | 40816268 | PubTator, text mining | PubMed |
| Complex II assembly drives metabolic adaptation to OXPHOS dysfunction. | Sci Adv | 2025 | 40815660 | PubTator, text mining | PubMed |
| HNF4A ameliorates acute liver failure by inhibiting NCOA4-mediated ferritinophagy. | Sci Rep | 2025 | 40804084 | PubTator, text mining | PubMed |
| Calcium phosphate-mineralized nanoplatform for enhanced ferroptosis and synergistic anti-PDL1 therapy in triple-negative breast cancer through multi-pathway targeting. | Acta Biomater | 2025 | 40784444 | PubTator, text mining | PubMed |
| Bioactive LDH nanoplatforms for cancer therapy: Advances in modulating programmed cell death. | Mater Today Bio | 2025 | 40761508 | PubTator, text mining | PubMed |
| De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. | Nat Commun | 2025 | 40738904 | PubTator, text mining | PubMed |
| The genetic puzzle of rheumatoid arthritis: Causes, progression, and treatment. | Biochem Biophys Rep | 2025 | 40734997 | PubTator, text mining | PubMed |
Design, synthesis and biological evaluation of N-pyridinyl ureidobenzenesulfonates and their hydrochloride salts as novel water-soluble dihydroorotate dehydrogenase inhibitors inducing differentiation of acute myeloid leukemia cells. | RSC Med Chem | 2025 | 40734665 | PubTator, text mining | PubMed |
| DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target. | Redox Biol | 2025 | 40716151 | PubTator, text mining | PubMed |
| The deubiquitinase USP24 suppresses ferroptosis in triple-negative breast cancer by stabilizing DHODH protein. | Cell Death Dis | 2025 | 40715045 | PubTator, text mining | PubMed |
| Construction of a De Novo Nucleotide Biosynthesis Pathway in Artificial Cells for RNA Transcription. | J Am Chem Soc | 2025 | 40708544 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1723/papers?page=8